You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 1 No. 2, August 1959 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effects of Reserpine, Iproniazid (Marsilid), and Triiodothyronine (Trionine), and of Reserpine Alone

A Comparative Study in One Hundred Seventeen Mentally Ill Patients of Various Diagnostic Categories

WILLIAM J. GALLAGHER, M.D.; ALLA B. SCHROEPPEL, M.D.; CARL C. PFEIFFER, Ph.D., M.D.

AMA Arch Gen Psychiatry 1959;1(2):215-222.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Tranquilizing drugs in adequate dosage tend to lessen anxiety and tension. They reduce overactivity, hostility, and destructiveness. They may, however, have certain undesirable side-effects, such as excessive weight gain, persistent drowsiness, a reduced capacity for motor functioning, and a reduced capacity for intellectual and emotional release.1,2 They are also ineffective in depressions, suicidal trends, and feeding problems. They may even increase these latter mental symptoms.

We began studies with iproniazid ( Marsilid) and deserpidine, a Rauwolfia alkaloid, in 1955 in chronic schizophrenia.3 Iproniazid is an inhibitor of the brain enzyme which metabolizes serotonin,4 and it decreases the depressant effect of deserpidine or reserpine in schizophrenic patients. It was observed then that a greater weight gain occurred with this drug combination than with either drug alone. Therefore, iproniazid was used alone or with reserpine in depressed feedingproblem patients in our Acute Hospital Di . . . [Full Text PDF of this Article]


Author Affiliations

Manteno, Ill.; Emory University, Ga.

Manteno State Hospital (Drs. Gallagher and Schroeppel). Professor of Pharmacology, Emory University School of Medicine (Dr. Pfeiffer).


Footnotes

Submitted for publication Oct. 29, 1958.

Reserpine was supplied through the courtesy of Hoffmann-La Roche, Inc., Nutley, N. J.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1959 American Medical Association. All Rights Reserved.